Ossium Health

Ossium Health is a bioengineering company developing the world's first bank of on-demand bone marrow.

Ossium's mission is to deploy cellular therapeutics and bioengineering to produce lasting gains in the health, vitality, and longevity of human beings.

Ossium Health was founded in 2016 by Kevin Caldwell and Erik Woods. The company is headquartered in San Francisco, California, with an office in Indianapolis, Indiana.

 

Ossium leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases. Its recovery process ensures that the bone marrow is phenotypically and functionally equivalent to cells from living donors. The product is then cryopreserved and stored indefinitely until requested by a treating physician.

 

Ossium works with Organ Procurement Organizations (OPOs) that represent just over half of all organ donors in the U.S. to recover viable vertebral bodies for bone marrow and orthopedic donations.

 

Ossium launched Ossigraft™, an orthopedic product for the repair, replacement, and reconstruction of musculoskeletal defects. This product is derived from the same vertebral bodies as Ossium’s other products, and provides another opportunity to honor the precious gift of donated tissue. This product is slated to enter the clinic in the second half of 2023.

 

Ossium is backed by General Catalyst, CPMG, Vivo Capital, First Round Capital, Alumni Ventures, Manta Ray Ventures, XYZ Capital, Asahi Kasei, and others. The company raised $52M in a Series C round on Jul 25, 2023. This brings Ossium's total funding to $125.4M to date.

 

 

  • Year founded: 2016
  • Funding Info: $125.4M over 4 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: San Francisco
  • State: California
  • Country: United States
Related businesses